BRAF and melanoma: RAF inhibitors such as dabrafinib have been shown to be effective in BRAF-mutant melanomas; however, in BRAF-mutant melanomas with concurrent NF1 mutations, RAF inhibitors are less effective due to remaining hyperactive RAS signaling (Maertens et al., 2013).